Literature DB >> 24197652

Retrospective analysis of 1,226 Chinese patients with haemophilia in a single medical centre.

Min Xuan1, Feng Xue, Rongfeng Fu, Yanhui Yang, Lei Zhang, Mengsu Tian, Renchi Yang.   

Abstract

Haemophilia A (HA) and B (HB) are X-linked congenital disorders caused by deficiencies of Factor VIII and FIX. Being the world's most populous country, China potentially has a large population of haemophilia patients. During the last decade, no studies have been published regarding the clinical information of haemophilia in China. A retrospective study was conducted in patients with HA and HB referred to Tianjin Haemophilia Centre between 2002 and 2012. We identified 1,226 males with haemophilia (1,019 HA and 207 HB). The results revealed that activate partial thromboplastin time was negatively correlated plasma factor level of person with haemophilia. Our data did not offer sufficient evidence of any relationship existed between disease severity and risk or site of haemorrhage. There was a trend toward a higher inhibitor incidence induced by plasma-derived factor VIII products, than by recombinant FVIII (rFVIII) alone. It seemed that second generation of rFVIII more likely developed inhibitor, and first generation of rFVIII was nevertheless more closely connected to high-titer inhibitor. We found that delay in diagnosis and blood-borne infections were significantly reduced, while the joint deformity rate did not decrease despite the wide variety of products to choose from in this decade. The development of inhibitor still remains a major challenge in replacement therapy in haemophilia.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24197652     DOI: 10.1007/s11239-013-1009-6

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  16 in total

Review 1.  The manufacturing process of recombinant factor VIII, recombinate.

Authors:  E Gomperts; R Lundblad; R Adamson
Journal:  Transfus Med Rev       Date:  1992-10

2.  The prevalence of factor VIII inhibitors and genetic aspects of inhibitor development in Chinese patients with haemophilia A.

Authors:  X F Wang; Y Q Zhao; R C Yang; J S Wu; J Sun; X S Zhang; Q L Ding; H L Ge; H L Wang
Journal:  Haemophilia       Date:  2010-03-12       Impact factor: 4.287

Review 3.  Inhibitor incidence with recombinant vs. plasma-derived FVIII in previously untreated patients with severe hemophilia A: homogeneous results from four published observational studies.

Authors:  T Calvez; Y Laurian; J Goudemand
Journal:  J Thromb Haemost       Date:  2007-11-23       Impact factor: 5.824

4.  Nondisclosure of human immunodeficiency virus and hepatitis C virus coinfection in a patient with hemophilia: medical and ethical considerations.

Authors:  R Kulkarni; A B Scott-Emuakpor; H Brody; W B Weil; M V Ragni; R Gera
Journal:  J Pediatr Hematol Oncol       Date:  2001 Mar-Apr       Impact factor: 1.289

5.  Hemophilic pseudotumor in chinese patients: a retrospective single-centered analysis of 14 cases.

Authors:  Feng Xue; Chaoxia Sun; Tao Sui; Lei Zhang; Lihui Jiang; Renchi Yang
Journal:  Clin Appl Thromb Hemost       Date:  2010-05-11       Impact factor: 2.389

6.  Inhibitor treatment in haemophilias A and B: summary statement for the 2006 international consensus conference.

Authors:  E Berntorp; A Shapiro; J Astermark; V S Blanchette; P W Collins; D Dimichele; C Escuriola; C R M Hay; W K Hoots; C A Leissinger; C Negrier; J Oldenburg; K Peerlinck; M T Reding; C Hart
Journal:  Haemophilia       Date:  2006-12       Impact factor: 4.287

Review 7.  Recombinant factor VIII concentrates.

Authors:  Massimo Franchini; Giuseppe Lippi
Journal:  Semin Thromb Hemost       Date:  2010-07-14       Impact factor: 4.180

Review 8.  Intensive exposure to factor VIII is a risk factor for inhibitor development in mild hemophilia A.

Authors:  A Sharathkumar; D Lillicrap; V S Blanchette; M Kern; J Leggo; A M Stain; L Brooker; M D Carcao
Journal:  J Thromb Haemost       Date:  2003-06       Impact factor: 5.824

9.  Retrospective analysis of 1312 patients with haemophilia and related disorders in a single Chinese institute.

Authors:  L Zhang; H Li; H Zhao; X Zhang; L Ji; R Yang
Journal:  Haemophilia       Date:  2003-11       Impact factor: 4.287

Review 10.  Haemophilia care in China: achievements of a decade of World Federation of Hemophilia treatment centre twinning activities.

Authors:  M-C Poon; K-H Luke
Journal:  Haemophilia       Date:  2008-07-15       Impact factor: 4.287

View more
  3 in total

1.  Analysis of hospitalization of people with hemophilia-12 years of experience in a single center.

Authors:  Cuiyun Qu; Wei Liu; Lingling Chen; Lei Zhang; Feng Xue; Renchi Yang
Journal:  Res Pract Thromb Haemost       Date:  2022-07-21

Review 2.  The Impact of Recombinant Versus Plasma-Derived Factor VIII Concentrates on Inhibitor Development in Previously Untreated Patients With Hemophilia A: A 2021 Update of a Systematic Review and Meta-Analysis.

Authors:  Kelvin Kohar; Stephanie A Prayogo; Lowilius Wiyono
Journal:  Cureus       Date:  2022-06-16

3.  [A phase Ⅲ multi-center clinical trial on safety and efficacy of a domestic plasma derived factor Ⅸ for the treatment of patients with hemophilia B].

Authors:  W Liu; R F Fu; Y W Zhou; Y Chen; J Yin; Z Q Yu; L H Yang; M F Wang; H Bi; Z P Zhou; X S Zhang; J L Xia; R C Yang
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2018-05-14
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.